Aflibercept ophthalmic solution

DRUG2 trials

Sponsors

Alcon Research

Conditions

Choroidal NeovascularizationNeovascular Age-Related Macular Degeneration

Phase 3

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

CompletedNCT02307682

Alcon ResearchChoroidal Neovascularization, Neovascular Age-Related Macular Degeneration

Start: 2014-12-08End: 2018-03-28Updated: 2025-01-16

Efficacy and Safety of RTH258 Versus Aflibercept - Study 2

CompletedNCT02434328

Alcon ResearchChoroidal Neovascularization, Neovascular Age-Related Macular Degeneration

Start: 2015-07-28End: 2018-03-08Updated: 2025-01-16

Related Papers

Effect of Brolucizumab and Aflibercept on the Maximum Thickness of Pigment Epithelial Detachments and Sub-Retinal Pigment Epithelium Fluid in HAWK and HARRIER.

2024-07-191 citations

Bacillary Layer Detachment in Neovascular Age-Related Macular Degeneration from a Phase III Clinical Trial.

2024-02-138 citations

Literature review and proposal of best practice for ophthalmologists: monitoring of patients following intravitreal brolucizumab therapy.

2022-02-016 citations

Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.

2021-12-277 citations

Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER.

2020-11-15250 citations

Antibodies to watch in 2020.

2020-01-01328 citations

HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration

Ophthalmology2019-04-12870 citations